Skip to main content
Erschienen in: Obesity Surgery 2/2020

17.10.2019 | Original Contributions

Lipoprotein(a) Change After Sleeve Gastrectomy Is Affected by the Presence of Metabolic Syndrome

verfasst von: Silvia Paredes, Marta Alves, Maria Lopes Pereira, Olinda Marques, Laura Ribeiro

Erschienen in: Obesity Surgery | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Patients with metabolic syndrome (MetS) are at high risk of developing cardiovascular disease (CVD) and lipoprotein(a) (Lp(a)) is an independent risk factor for CVD. This study aimed to determine the effect of vertical sleeve gastrectomy (VSG)–induced weight loss on Lp(a) levels in obese individuals.

Methods

Patients submitted to VSG from January 2011 to July 2015 were included. Anthropometric and metabolic parameters were recorded before and 12 months after surgery. Univariate analysis identified associations between Lp(a) and anthropometry and metabolic parameters, and the logistic regression predictors of Lp(a) decrease after VSG.

Results

MetS was present in 47% of the 330 patients involved. Patients with MetS had higher body mass index (BMI) and triglyceride levels and were more insulin-resistant. No differences were found between groups respecting Lp(a) levels prior to surgery (15.2 mg/dL vs. 15.0 mg/dL, p = 0.795). After surgery, patients without MetS had a decrease in Lp(a) levels (14.7 mg/dL vs. 12.3 mg/dL, p = 0.006), while MetS patients showed no differences (13.9 mg/dL vs. 14.6 mg/dL, p = 0.302). The regression model evidenced that older age and Δ HDL-c were predictors of Lp(a) decrease, whereas the greater the number of MetS components and lower estimated BF% loss, the lesser odds of decreasing Lp(a) after surgery.

Conclusions

Despite a global improvement of conventional CVD risk factors, only individuals without MetS showed a decrease of Lp(a) levels after VSG. Further studies should explore not only the pathophysiological mechanisms underlying the absence of decrease of Lp(a) levels in MetS patients, but also its impact on the metabolic beneficial changes usually observed after VSG.
Literatur
1.
Zurück zum Zitat Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009;53(21):1925–32.PubMed Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009;53(21):1925–32.PubMed
2.
Zurück zum Zitat Moller DE, Kaufman KD. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med. 2005;56:45–62.PubMed Moller DE, Kaufman KD. Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med. 2005;56:45–62.PubMed
3.
Zurück zum Zitat Kolovou GD, Anagnostopoulou KK, Cokkinos DV. Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad Med J. 2005;81(956):358–66.PubMedPubMedCentral Kolovou GD, Anagnostopoulou KK, Cokkinos DV. Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad Med J. 2005;81(956):358–66.PubMedPubMedCentral
4.
Zurück zum Zitat Batsis JA, Romero-Corral A, Collazo-Clavell ML, et al. Effect of bariatric surgery on the metabolic syndrome: a population-based, long-term controlled study. Mayo Clin Proc. 2008;83(8):897–907.PubMedPubMedCentral Batsis JA, Romero-Corral A, Collazo-Clavell ML, et al. Effect of bariatric surgery on the metabolic syndrome: a population-based, long-term controlled study. Mayo Clin Proc. 2008;83(8):897–907.PubMedPubMedCentral
5.
Zurück zum Zitat Lee WJ, Huang MT, Wang W, et al. Effects of obesity surgery on the metabolic syndrome. Arch Surg. 2004;139(10):1088–92.PubMed Lee WJ, Huang MT, Wang W, et al. Effects of obesity surgery on the metabolic syndrome. Arch Surg. 2004;139(10):1088–92.PubMed
6.
Zurück zum Zitat Van Osdol AD, Grover BT, Borgert AJ, et al. Impact of laparoscopic Roux-en-Y gastric bypass versus sleeve gastrectomy on postoperative lipid values. Surg Obes Relat Dis. 2017;13(3):399–403.PubMed Van Osdol AD, Grover BT, Borgert AJ, et al. Impact of laparoscopic Roux-en-Y gastric bypass versus sleeve gastrectomy on postoperative lipid values. Surg Obes Relat Dis. 2017;13(3):399–403.PubMed
7.
Zurück zum Zitat Benaiges D, Flores-Le-Roux JA, Pedro-Botet J, et al. Impact of restrictive (sleeve gastrectomy) vs hybrid bariatric surgery (Roux-en-Y gastric bypass) on lipid profile. Obes Surg. 2012;22(8):1268–75.PubMed Benaiges D, Flores-Le-Roux JA, Pedro-Botet J, et al. Impact of restrictive (sleeve gastrectomy) vs hybrid bariatric surgery (Roux-en-Y gastric bypass) on lipid profile. Obes Surg. 2012;22(8):1268–75.PubMed
8.
Zurück zum Zitat Gomez-Martin JM, Balsa JA, Aracil E, et al. Beneficial changes on plasma apolipoproteins A and B, high density lipoproteins and oxidized low density lipoproteins in obese women after bariatric surgery: comparison between gastric bypass and sleeve gastrectomy. Lipids Health Dis. 2018;17(1):145.PubMedPubMedCentral Gomez-Martin JM, Balsa JA, Aracil E, et al. Beneficial changes on plasma apolipoproteins A and B, high density lipoproteins and oxidized low density lipoproteins in obese women after bariatric surgery: comparison between gastric bypass and sleeve gastrectomy. Lipids Health Dis. 2018;17(1):145.PubMedPubMedCentral
9.
Zurück zum Zitat Waldeyer C, Makarova N, Zeller T, et al. Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. Eur Heart J. 2017;38(32):2490–8.PubMedPubMedCentral Waldeyer C, Makarova N, Zeller T, et al. Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. Eur Heart J. 2017;38(32):2490–8.PubMedPubMedCentral
10.
Zurück zum Zitat Bennet A, Di Angelantonio E, Erqou S, et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med. 2008;168(6):598–608.PubMed Bennet A, Di Angelantonio E, Erqou S, et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med. 2008;168(6):598–608.PubMed
11.
Zurück zum Zitat Rhee EJ, Cho JH, Lee DY, et al. Insulin resistance contributes more to the increased risk for diabetes development in subjects with low lipoprotein(a) level than insulin secretion. PLoS One. 2017;12(5):e0177500.PubMedPubMedCentral Rhee EJ, Cho JH, Lee DY, et al. Insulin resistance contributes more to the increased risk for diabetes development in subjects with low lipoprotein(a) level than insulin secretion. PLoS One. 2017;12(5):e0177500.PubMedPubMedCentral
12.
Zurück zum Zitat Kelly E, Hemphill L. Lipoprotein(a): a lipoprotein whose time has come. Curr Treat Options Cardiovasc Med. 2017;19(7):48.PubMed Kelly E, Hemphill L. Lipoprotein(a): a lipoprotein whose time has come. Curr Treat Options Cardiovasc Med. 2017;19(7):48.PubMed
13.
Zurück zum Zitat Bermudez V, Rojas J, Salazar J, et al. Variations of lipoprotein(a) levels in the metabolic syndrome: a report from the Maracaibo City Metabolic Syndrome Prevalence Study. J Diabetes Res. 2013;2013:416451.PubMedPubMedCentral Bermudez V, Rojas J, Salazar J, et al. Variations of lipoprotein(a) levels in the metabolic syndrome: a report from the Maracaibo City Metabolic Syndrome Prevalence Study. J Diabetes Res. 2013;2013:416451.PubMedPubMedCentral
14.
Zurück zum Zitat Vonbank A, Saely CH, Rein P, et al. Lipoprotein (a), the metabolic syndrome and vascular risk in angiographied coronary patients. J Clin Endocrinol Metab. 2016;101(8):3199–203.PubMed Vonbank A, Saely CH, Rein P, et al. Lipoprotein (a), the metabolic syndrome and vascular risk in angiographied coronary patients. J Clin Endocrinol Metab. 2016;101(8):3199–203.PubMed
15.
Zurück zum Zitat Sung KC, Wild SH, Byrne CD. Lipoprotein (a), metabolic syndrome and coronary calcium score in a large occupational cohort. Nutr Metab Cardiovasc Dis. 2013;23(12):1239–46.PubMed Sung KC, Wild SH, Byrne CD. Lipoprotein (a), metabolic syndrome and coronary calcium score in a large occupational cohort. Nutr Metab Cardiovasc Dis. 2013;23(12):1239–46.PubMed
16.
Zurück zum Zitat Kotani K, Shimohiro H, Adachi S, et al. Relationship between lipoprotein(a), metabolic syndrome, and carotid atherosclerosis in older Japanese people. Gerontology. 2008;54(6):361–4.PubMed Kotani K, Shimohiro H, Adachi S, et al. Relationship between lipoprotein(a), metabolic syndrome, and carotid atherosclerosis in older Japanese people. Gerontology. 2008;54(6):361–4.PubMed
17.
Zurück zum Zitat Kiortsis DN, Tzotzas T, Giral P, et al. Changes in lipoprotein(a) levels and hormonal correlations during a weight reduction program. Nutr Metab Cardiovasc Dis. 2001;11(3):153–7.PubMed Kiortsis DN, Tzotzas T, Giral P, et al. Changes in lipoprotein(a) levels and hormonal correlations during a weight reduction program. Nutr Metab Cardiovasc Dis. 2001;11(3):153–7.PubMed
18.
Zurück zum Zitat Wood RJ, Volek JS, Davis SR, et al. Effects of a carbohydrate-restricted diet on emerging plasma markers for cardiovascular disease. Nutr Metab (Lond). 2006;3:19. Wood RJ, Volek JS, Davis SR, et al. Effects of a carbohydrate-restricted diet on emerging plasma markers for cardiovascular disease. Nutr Metab (Lond). 2006;3:19.
19.
Zurück zum Zitat Berk KA, Yahya R, Verhoeven AJM, et al. Effect of diet-induced weight loss on lipoprotein(a) levels in obese individuals with and without type 2 diabetes. Diabetologia. 2017;60(6):989–97.PubMedPubMedCentral Berk KA, Yahya R, Verhoeven AJM, et al. Effect of diet-induced weight loss on lipoprotein(a) levels in obese individuals with and without type 2 diabetes. Diabetologia. 2017;60(6):989–97.PubMedPubMedCentral
20.
Zurück zum Zitat Williams DB, Hagedorn JC, Lawson EH, et al. Gastric bypass reduces biochemical cardiac risk factors. Surg Obes Relat Dis. 2007;3(1):8–13.PubMed Williams DB, Hagedorn JC, Lawson EH, et al. Gastric bypass reduces biochemical cardiac risk factors. Surg Obes Relat Dis. 2007;3(1):8–13.PubMed
21.
Zurück zum Zitat Ram E, Vishne T, Magazanik A, et al. Changes in blood lipid levels following silastic ring vertical gastroplasty. Obes Surg. 2007;17(10):1292–6.PubMed Ram E, Vishne T, Magazanik A, et al. Changes in blood lipid levels following silastic ring vertical gastroplasty. Obes Surg. 2007;17(10):1292–6.PubMed
22.
Zurück zum Zitat Woodard GA, Peraza J, Bravo S, et al. One year improvements in cardiovascular risk factors: a comparative trial of laparoscopic Roux-en-Y gastric bypass vs. adjustable gastric banding. Obes Surg. 2010;20(5):578–82.PubMed Woodard GA, Peraza J, Bravo S, et al. One year improvements in cardiovascular risk factors: a comparative trial of laparoscopic Roux-en-Y gastric bypass vs. adjustable gastric banding. Obes Surg. 2010;20(5):578–82.PubMed
23.
Zurück zum Zitat Fried M, Yumuk V, Oppert JM, et al. Interdisciplinary European guidelines on metabolic and bariatric surgery. Obes Facts. 2013;6(5):449–68.PubMedPubMedCentral Fried M, Yumuk V, Oppert JM, et al. Interdisciplinary European guidelines on metabolic and bariatric surgery. Obes Facts. 2013;6(5):449–68.PubMedPubMedCentral
24.
Zurück zum Zitat Yumuk V, Tsigos C, Fried M, et al. European guidelines for obesity management in adults. Obes Facts. 2015;8(6):402–24.PubMedPubMedCentral Yumuk V, Tsigos C, Fried M, et al. European guidelines for obesity management in adults. Obes Facts. 2015;8(6):402–24.PubMedPubMedCentral
25.
Zurück zum Zitat Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–357.PubMed Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–357.PubMed
26.
Zurück zum Zitat American DA. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S13–27. American DA. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S13–27.
27.
Zurück zum Zitat Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5.PubMed Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5.PubMed
28.
Zurück zum Zitat Gomez-Ambrosi J, Silva C, Galofre JC, et al. Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity. Int J Obes. 2012;36(2):286–94. Gomez-Ambrosi J, Silva C, Galofre JC, et al. Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity. Int J Obes. 2012;36(2):286–94.
29.
Zurück zum Zitat Flegal KM, Shepherd JA, Looker AC, et al. Comparisons of percentage body fat, body mass index, waist circumference, and waist-stature ratio in adults. Am J Clin Nutr. 2009;89(2):500–8.PubMed Flegal KM, Shepherd JA, Looker AC, et al. Comparisons of percentage body fat, body mass index, waist circumference, and waist-stature ratio in adults. Am J Clin Nutr. 2009;89(2):500–8.PubMed
30.
Zurück zum Zitat Rivas-Crespo MF. Comment on Boyko and Jensen. Do we know what homeostatis model assessment measures? If not, does it matter? Diabetes Care. 2007;30:2725–8. Diabetes Care. 2015 Dec;38(12):e213 Rivas-Crespo MF. Comment on Boyko and Jensen. Do we know what homeostatis model assessment measures? If not, does it matter? Diabetes Care. 2007;30:2725–8. Diabetes Care. 2015 Dec;38(12):e213
31.
Zurück zum Zitat Tremblay AJ, Morrissette H, Gagne JM, et al. Validation of the Friedewald formula for the determination of low-density lipoprotein cholesterol compared with beta-quantification in a large population. Clin Biochem. 2004;37(9):785–90.PubMed Tremblay AJ, Morrissette H, Gagne JM, et al. Validation of the Friedewald formula for the determination of low-density lipoprotein cholesterol compared with beta-quantification in a large population. Clin Biochem. 2004;37(9):785–90.PubMed
33.
Zurück zum Zitat Chang Y, Ryu S, Suh BS, et al. Impact of BMI on the incidence of metabolic abnormalities in metabolically healthy men. Int J Obes. 2012;36(9):1187–94. Chang Y, Ryu S, Suh BS, et al. Impact of BMI on the incidence of metabolic abnormalities in metabolically healthy men. Int J Obes. 2012;36(9):1187–94.
34.
Zurück zum Zitat Davila-Batista V, Molina AJ, Vilorio-Marques L, et al. Net contribution and predictive ability of the CUN-BAE body fatness index in relation to cardiometabolic conditions. Eur J Nutr. 2019;58(5):1853–186.PubMedPubMedCentral Davila-Batista V, Molina AJ, Vilorio-Marques L, et al. Net contribution and predictive ability of the CUN-BAE body fatness index in relation to cardiometabolic conditions. Eur J Nutr. 2019;58(5):1853–186.PubMedPubMedCentral
35.
Zurück zum Zitat Garciacaballero M, Reyes-Ortiz A, Garcia M, et al. Changes of body composition in patients with BMI 23-50 after tailored one anastomosis gastric bypass (BAGUA): influence of diabetes and metabolic syndrome. Obes Surg. 2014;24(12):2040–7.PubMed Garciacaballero M, Reyes-Ortiz A, Garcia M, et al. Changes of body composition in patients with BMI 23-50 after tailored one anastomosis gastric bypass (BAGUA): influence of diabetes and metabolic syndrome. Obes Surg. 2014;24(12):2040–7.PubMed
36.
Zurück zum Zitat Brochu M, Tchernof A, Turner AN, et al. Is there a threshold of visceral fat loss that improves the metabolic profile in obese postmenopausal women? Metabolism. 2003;52(5):599–604.PubMed Brochu M, Tchernof A, Turner AN, et al. Is there a threshold of visceral fat loss that improves the metabolic profile in obese postmenopausal women? Metabolism. 2003;52(5):599–604.PubMed
37.
Zurück zum Zitat Vaverkova H, Karasek D, Halenka M, et al. Inverse association of lipoprotein (a) with markers of insulin resistance in dyslipidemic subjects. Physiol Res. 2017;66(Supplementum 1):S113–S20.PubMed Vaverkova H, Karasek D, Halenka M, et al. Inverse association of lipoprotein (a) with markers of insulin resistance in dyslipidemic subjects. Physiol Res. 2017;66(Supplementum 1):S113–S20.PubMed
38.
Zurück zum Zitat Chennamsetty I, Claudel T, Kostner KM, et al. Farnesoid X receptor represses hepatic human APOA gene expression. J Clin Invest. 2011;121(9):3724–34.PubMedPubMedCentral Chennamsetty I, Claudel T, Kostner KM, et al. Farnesoid X receptor represses hepatic human APOA gene expression. J Clin Invest. 2011;121(9):3724–34.PubMedPubMedCentral
39.
Zurück zum Zitat Bozadjieva N, Heppner KM, Seeley RJ. Targeting FXR and FGF19 to treat metabolic diseases-lessons learned from bariatric surgery. Diabetes. 2018;67(9):1720–8.PubMedPubMedCentral Bozadjieva N, Heppner KM, Seeley RJ. Targeting FXR and FGF19 to treat metabolic diseases-lessons learned from bariatric surgery. Diabetes. 2018;67(9):1720–8.PubMedPubMedCentral
40.
Zurück zum Zitat Ethanic M, Stanimirov B, Pavlovic N, et al. Pharmacological applications of bile acids and their derivatives in the treatment of metabolic syndrome. Front Pharmacol. 2018;9:1382.PubMedPubMedCentral Ethanic M, Stanimirov B, Pavlovic N, et al. Pharmacological applications of bile acids and their derivatives in the treatment of metabolic syndrome. Front Pharmacol. 2018;9:1382.PubMedPubMedCentral
41.
Zurück zum Zitat Ryan KK, Tremaroli V, Clemmensen C, et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature. 2014;509(7499):183–8.PubMedPubMedCentral Ryan KK, Tremaroli V, Clemmensen C, et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature. 2014;509(7499):183–8.PubMedPubMedCentral
42.
Zurück zum Zitat Ma H, Patti ME. Bile acids, obesity, and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014;28(4):573–83.PubMedPubMedCentral Ma H, Patti ME. Bile acids, obesity, and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014;28(4):573–83.PubMedPubMedCentral
43.
Zurück zum Zitat Ghosh Laskar M, Eriksson M, Rudling M, et al. Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C-III. J Intern Med. 2017;281(6):575–85.PubMed Ghosh Laskar M, Eriksson M, Rudling M, et al. Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C-III. J Intern Med. 2017;281(6):575–85.PubMed
44.
Zurück zum Zitat Langhi C, Le May C, Kourimate S, et al. Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes. FEBS Lett. 2008;582(6):949–55.PubMed Langhi C, Le May C, Kourimate S, et al. Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes. FEBS Lett. 2008;582(6):949–55.PubMed
45.
Zurück zum Zitat O’Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139(12):1483–92.PubMed O’Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139(12):1483–92.PubMed
46.
Zurück zum Zitat Chennamsetty I, Claudel T, Kostner KM, et al. FGF19 signaling cascade suppresses APOA gene expression. Arterioscler Thromb Vasc Biol. 2012;32(5):1220–7.PubMed Chennamsetty I, Claudel T, Kostner KM, et al. FGF19 signaling cascade suppresses APOA gene expression. Arterioscler Thromb Vasc Biol. 2012;32(5):1220–7.PubMed
47.
Zurück zum Zitat Gallego-Escuredo JM, Gomez-Ambrosi J, Catalan V, et al. Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients. Int J Obes. 2015;39(1):121–9. Gallego-Escuredo JM, Gomez-Ambrosi J, Catalan V, et al. Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients. Int J Obes. 2015;39(1):121–9.
49.
Zurück zum Zitat Suzuki T, Aoyama J, Hashimoto M, et al. Correlation between postprandial bile acids and body fat mass in healthy normal-weight subjects. Clin Biochem. 2014;47(12):1128–31.PubMed Suzuki T, Aoyama J, Hashimoto M, et al. Correlation between postprandial bile acids and body fat mass in healthy normal-weight subjects. Clin Biochem. 2014;47(12):1128–31.PubMed
Metadaten
Titel
Lipoprotein(a) Change After Sleeve Gastrectomy Is Affected by the Presence of Metabolic Syndrome
verfasst von
Silvia Paredes
Marta Alves
Maria Lopes Pereira
Olinda Marques
Laura Ribeiro
Publikationsdatum
17.10.2019
Verlag
Springer US
Erschienen in
Obesity Surgery / Ausgabe 2/2020
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-019-04212-9

Weitere Artikel der Ausgabe 2/2020

Obesity Surgery 2/2020 Zur Ausgabe

Letter to Editor/LED Reply

Commentary: Cancer after the OAGB-MGB

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.